PSU, Nova Health, and AR Research sign MoU for commercial R&D innovation

        On 19 July 2022, PSU joined Nova Health Company Limited, and AR Research Company Limited, to sign an MoU for “Research and development work/innovation for commercial use”. PSU Vice President for Research and Innovation Assoc. Prof. Sunton Wongsiri, M.D. welcomed the executives of the two companies, and joined the signing ceremony at the President’s Office, PSU Hat Yai Campus.

        Prof. Sunton explained that the signing ceremony represents a milestone in the collaboration between the university and the private sector, and that the partnership is expected to bring research and innovation into commercial use for the benefit of people, agencies, and society, resulting in the sustainable growth of Thailand's economy.

        PSU’s research expertise in medication, health, cosmetics, and other aspects meet the companies’ needs. The university’s research, knowledge development, and production technology have been continuously recognized, along with its history of fruitful collaboration with the private sector, resulting in a variety of practical applications.

        This cooperation focuses on joint research and development of medical products and health products such as food, food supplements, cosmetics, and traditional Thai medicine, to promote, support, and develop knowledgeable staff with skills and expertise. The cooperation encourages the practical implementation of research results, along with providing academic support, advice, and other related activities.

        PSU and AR Research Co., Ltd. promote, support, and develop research and development projects/innovations, immunotherapy, cell therapy, and other innovations with commercial application. Concrete aims include pushing research results or research products to industrial and public use; establishing a GMP-certified manufacturing facility and clinical research; and creating products to use for immunotherapy or cell therapy services to increase cancer patients’ access to precision treatment. Further aims include the expansion of collaborative relationships in research and development studies with external agencies both domestically and abroad; the development of medical staff; and increasing the efficiency of teaching and learning at the graduate level, alongside infrastructure development.